Kolb, Ryan
De, Umasankar
Khan, Sajid http://orcid.org/0000-0003-1331-8846
Luo, Yuewan
Kim, Myung-Chul
Yu, Haijun
Wu, Chaoyan
Mo, Jiao
Zhang, Xin
Zhang, Peiyi
Zhang, Xuan http://orcid.org/0000-0001-6062-6708
Borcherding, Nicholas
Koppel, Daniel
Fu, Yang-Xin http://orcid.org/0000-0002-4809-825X
Zheng, Song Guo
Avram, Dorina
Zheng, Guangrong http://orcid.org/0000-0002-8106-6663
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
Zhang, Weizhou http://orcid.org/0000-0002-8236-0346
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA200673, CA203834)
U.S. Department of Health & Human Services | National Institutes of Health
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (BC180227)
Article History
Received: 6 May 2020
Accepted: 1 February 2021
First Online: 24 February 2021
Competing interests
: S.K., Xuan, Z., G.Z., and D.Z. are inventors of two pending patent applications for the use of BCL-XL PROTACs as senolytic and antitumor agents. G.Z. and D.Z. are co-founders of, and have equity in, Dialectic Therapeutics, which develops BCL-XL PROTACs for the treatment of cancer. The other authors have no competing interests.